Introduction
Since the report of the rst human immunode ciency virus (HIV) case in 1981, the acquired immunode ciency syndrome (AIDS) has become the fourth leading cause of death worldwide. e United Nations estimates that there are now 40 million people living with HIV/ AIDS. us, it is urgent to develop novel therapeutic and preventative agents to reduce the transmission of HIV. Because the majority of HIV infections are acquired through heterosexual intercourse, it would be helpful if measures can be taken to stop or prevent the sexual transmission of HIV [1, 2] .
We have been focusing on identifying potent anti-HIV candidates derived from naturally occurring antimicrobial peptides (AMPs). ese peptides have been proven to have antimicrobial e ects on a broad range of bacteria, viruses, fungi, and parasites [3] [4] [5] [6] . Select amphibian and piscine AMPs are known to reduce infectivity of channel cat sh virus (CCV), frog virus 3 (FV3), and HIV [7, 8] . In addition, AMPs with anti-HIV activity have also been discovered from other sources, which include melittin and cecropin from insects [9] , cathelicidins and defensins from mammals [5, [10] [11] [12] [13] , and cyclotides (i.e. circular peptides) from plants [14] . We previously identi ed the most potent as well as the minimal anti-HIV fragments within human cathelicidin LL-37 [13] . A follow-up study showed that LL-37 fragments inhibited HIV reverse transcriptase in vitro [15] . It is also likely that the antiviral e ect of vitamin D is associated with the expression of human LL-37 in vivo [16] . We also found that BMAP-18, a fragment derived from bovine cathelicidin BMAP-27, is a HIV-1 inhibitor (EC50 = 0.83 g/ml) with a therapeutic index (TI) of 24 [13] . To identify additional templates, we have evaluated 30 peptides selected from the antimicrobial peptide database [17, 18] . e results of that peptide screening led to the identi cation of 10 HIV inhibitory peptides with EC50 values in the range of 1.0 to 10 g/ml [19] . is study extends the results of our previous studies by evaluating AMPs with di erent loop structures. ese peptides were designed using GLR-19 as a template. GLR-19 was previously de novo designed based on the antimicrobial peptide database [17, 19] . We also compared the stability of these peptide sca olds to the action of chymotrypsin. e results of the current study are reported herein.
Materials and Methods

Peptides
All the peptides were chemically synthesized using the solid-phase method and puri ed by HPLC to >95% (Genemed Synthesis, Inc., TX).
Anti-HIV assays
Anti-HIV-1 cytopathic e ect (CPE)-inhibition assays were performed as described [20] . In brief, serially diluted peptides were added to a 96-well round bottom microtiter plate in triplicate. CEM-SS cells at a concentration of 2.5 10 3 cells per well and HIV-1IIIB at the appropriate pre-determined titer were sequentially added to the microtiter plate. e cultures were incubated at 5% CO2/37°C for six days. Following the incubation, the microtiter plates were stained with XTT tetrazolium dye to evaluate the e cacy and toxicity of the test compound(s). Using 4-parameter curve tting, values of EC50 (50% inhibition of virus replication), and TC 50 (50% reduction in cell viability), as well as a therapeutic index (TI = TC 50 /EC 50 ), were determined for each peptide.
Antibacterial assays e antibacterial activity of the peptides was analyzed using the standard approach of microdilution [21] . e bacterial strains used were Escherichia coli K12 and Bacillus subtilis. In brief, small bacterial cultures were grown overnight. Fresh cultures were inoculated with a small aliquot of the overnight culture and incubated at 37oC until the optical density A600 of the culture reached ~0.5. e bacterial culture (90 l each) was then diluted to an A600 of 0.001 and partitioned into a 96-well plate with ~10 5 colony-forming units (CFU) per well. e cells were then treated with 10 l of the peptide at di erent concentrations, allowing the minimum inhibitory concentration (MIC) measurement for each. e assay was duplicated and repeated multiple times. e plate was then further incubated at 37oC overnight (~16 hrs) and read at 630 nm on a ChroMate 4300 microplate reader (GMI, MN).
High performance liquid chromatography (HPLC)
e retention time of the peptide was measured on a Waters HPLC system equipped with an analytical reverse-phase Waters symmetry C8 column (150 × 3.9 mm). e peptide was eluted by a gradient of acetonitrile (containing 1% TFA) from 5% to 95% at a ow rate of 1 ml/ min. e peptide peak was detected by UV at 254 nm.
Electrophoresis assays of peptide stability
Peptide (0.5 mM) and chymotrypsin (molar ratio 40:1) were mixed and incubated at 37oC in 10 mM PBS bu er (pH 8.0). An aliquot (20 µl) of the reaction was taken at di erent hours and immediately mixed with 10 µl of SDS loading bu er to terminate the action of the protease. Aliquots of the reactions were subsequently analyzed using 18% stacking tricine SDS-PAGE. e bands were stained by Coomassie Brilliant Blue R250 (Fisher). Images of the gels were taken and digitized in Photoshop 6.0 for band quanti cation.
Results
Engineering of HIV inhibitory peptides based on an AMP with a b-sheet structure
Our previous studies focused on linear peptides from which several HIV inhibitory candidates have been identi ed. ose peptides such as the GI-20 and BMAP-18 have a tendency to form amphipathic helical structures, especially when in complex with membranes [21] [22] [23] . In this study, BAMP-18 was included as a control and it showed a similar e cacy in Table 1 as reported previously [13] . To expand the conformation space, we shi ed our focus to AMPs with a -sheet structure. anatin is a natural AMP isolated from the insect Podisus maculiventris (i.e., the spined soldier bug) [24] .
is peptide was chosen because it has a simple hairpin structure with a single disul de bond (C11-C18) between the two strands ( Figure 1A) [25]. Two derivatives of thanatin were obtained. In the structure-based peptide 1 (SB1), the last residue Met of thanatin was substituted with Ile to reduce possible oxidation of the peptide. is peptide demonstrated activity against HIV-1 but poor activity against HSV-2 (Table 1) . To enhance the anti-HIV activity of SB1, residues K3, K4, and K17 were converted to arginines based on previous ndings from the AMP database [17, 18] . SB2, the arginine analog of SB1, indeed showed higher activity against HIV-1. However, these changes deprived SB1 of the weak activity against HSV-2 (Table 1) . Since there was no increase in cytotoxicity, the reduced EC50 value of SB2 directly translated into a greater TI (Table 1 ). e TI of SB2 reached 30, which is slightly greater than those (TI = 21-25) determined for GI-20 (derived from human LL-37), BMAP-18 (derived from cattle cathelicidin BMAP-27), and an arginine analog of dermaseptin S9 [13, 19] .
De novo design of peptides with various loop structures
We designed additional peptides using GLR-19 as the starting sequence. is peptide is a de novo designed peptide which is known to be inhibitory to HIV-1 [17, 19] . We found that GLR-19 also showed antiviral activity against HSV-2 (Table 1 ). To mimic the hairpin structure of thanatin, we introduced a disul de bond at di erent positions within GLR-19 ( Figure 1 ). In each case, the incorporation of a disul de bond into GLR-19 was at the expense of two leucines, which were replaced by cysteines. Initially, a disul de bond (yellow lines in Figure 1 ) was positioned between residues 2 and 18 (C2-C18) to generate a large loop structure. is disul de bond was shi ed to generate additional peptides with a reduced loop size ( Figure 1 ). We referred to these disul de bond-linked peptides as GLRC peptides since their sequences are composed of only G, L, R and C amino acid residues. GLRC-1, the peptide with the large 17-residue loop, yielded an EC50 greater than 100 µg/ml, which was the highest concentration evaluated in antiviral assays [13] . GLRC-2, however, the peptide with a middle-sized 13-residue loop, demonstrated the highest potency (EC50 = 1.81 µg/ml). When the size of the loop was furthered reduced to obtain GLRC-3, antiviral activity was reduced. In parallel antiviral assays, GLRC-2 also showed the best activity against HSV-2 compared to both GLRC-1 and GLRC-3 (Table 1) . ese results highlight the importance of the C4-C16 disul de linkage in GLRC-2. Consistent with this observation, GLRC-4 was also determined to be inactive when two di erent disul de bonds (C2-C18 and C6-C14) were applied in the peptide. However, the GLRC peptides with disul de bonds all had reduced activity against HSV-2 compared to the linear template GLR-19 (Table 1 ). e possibility that linear AMPs are generally more active than their disul de counterparts against HSV-2 remains to be tested.
Next, we further mimicked the sca old of SB2 by removing either the N-or the C-terminal residues outside of the loop (Figure 1) . When the C-terminal segment LLR was truncated, the resulting peptide GLRC-5 became inactive. In contrast, the peptide GLRC-6 remained active a er the N-terminally exposed residues, GLR, of GLRC-2 were removed. Another peptide (GLRC-7) was obtained by removing both the N-and C-terminal segments outside of the loop of GLRC-2. Like GLRC-5, GLRC-7 was inactive. ese results suggest that the C-terminal LLR segment of GLRC-2 is important for anti-HIV activity. We also evaluated if the sequence of the central fragment between the two Cys residues of GLRC-2 played a role in antiviral activity. To address this question, we altered the sequence order without changing the amino acid composition. To our surprise, the resulting peptide GLRC-8 was found to be inactive ( Table 2 ). We conclude that both the order of the central sequence and the C-terminal region of GLRC-2 play an important role in HIV inhibition.
Because these GLRC peptides are novel, we also evaluated their antibacterial activity using representative laboratory strains. Overall, these peptides showed poor activity against Gram-positive B. subtilis ( Table 2 ). In the case of Gram-negative E. coli K12, the most active peptide (MIC = 7.5 µM) was GLRC-3, the peptide with the smallest loop ( Figure 1 ). Peptides GLRC-1, GLRC-2, GLRC-6, and GLRC-8 showed similar anti-E. coli activity (MIC = 30 µM), indicating that the N-terminal segment GLR of GLRC-2 is dispensable for antibacterial activity. Interestingly, the least active peptide was determined to be GLRC-7, the shortest GLRC peptide with a 13-residue loop structure.
us, the C-terminal segment of GLRC-2 appears to be important also for bactericidal activity.
Peptide parameters that in uence activity
To provide further insight into the antimicrobial activities of these peptide constructs, we measured the retention times of the GLRC peptides by reverse-phase HPLC ( Table 2 ). e retention time is related to peptide hydrophobicity [23] . Other parameters such as net charge, hydrophobic residues% (pho% in Table 3 ), and Boman index [18] (i.e. protein binding potential) [3] were also calculated for the GRLC peptides using the prediction interface of the AMP database (http://aps.unmc.edu/AP/main.html) [18] and are included in Table  3 . While it is not obvious why GRLC-3 is most active against E. coli, the high potency of GLRC-2 against HIV-1 is likely to be due to high hydrophobicity of the peptide, which has the longest retention time (tR) ( Table 2 ).
Stability of the GLRC peptides to chymotrypsin
We also compared the stability of the GLRC peptides to the action of proteases such as chymotrypsin. Figure 2 shows the percentage of intact peptide a er protease treatment at 37oC for 4 hrs. For comparison, SB1 was also tested and was found to have 23% intact peptide remaining at 4 hrs. Compared to SB1, the linear template GLR-19, with 15.5% intact peptide remaining, was less stable ( Figure  2 ). Restraining the GLR-19 polypeptide chain with disul de bonds had a signi cant impact on peptide stability. First, we determined that peptide stability was related to the loop size: GLRC-2 > GLRC-1 > GLRC-3 ( Figure 1) . us, GLRC-2, with a medium-sized loop structure, acquired improved stability (>60% intact peptide) compared to SB1 (23% intact peptide, Figure 2 ). e stability of GLRC-2 increased by 4.4 fold relative to GLR-19. Note that GLRC-4, with two disul de bond patterns as in GLRC-1 (C2-C18) and GLRC-3 (C6-C14), did not gain additional stability to the protease, further indicating the importance of the C4-C16 disul de bond. Second, although GLRC-2 and GLRC-8 share the medium-sized loop, they had drastically di erent stability. It is likely that the sequence order in the loop determines the extent of overall packing of the peptide chain. ird, the segment outside of the loop appeared to be critical for GLRC-2 stability. In particular, removal of the N-terminal segment was detrimental, leading to complete degradation of the peptide in four hours. e C-terminal segment was less important with about 50% of the peptide remaining at 4 hrs. is is in contrast to the importance of the C-terminal segment for anti-HIV activity. Nevertheless, it is interesting to note that GLRC-2, which demonstrated the greatest activity against HIV-1 (Table 1) , was also the most stable to protease compared to the other GLRC peptides ( Figure  2 ).
Discussion
In order to identify AMP candidates as lead products for the development of topical microbicides, we have continued our e orts to search for potent anti-HIV peptides. In our previous studies [13, 19] , di erent engineering strategies were adopted. ese included database screening, sequence shu ing, and database-aided antiviral activity enhancement [26] . A er activity enhancement, several anti-HIV peptides in the helical family were obtained with TIs >20. e current study identi ed a β-hairpin peptide SB2 with a TI = 30 by using the same Lys-to-Arg mutational strategy [19] . It seemed that this strategy might be applicable to the improvement of anti-HIV activity of AMPs with di erent structural sca olds. e establishment of the antimicrobial peptide database facilitated bioinformatic analysis of natural AMPs from a de ned family or source [17, 18] . For example, the frequently occurring residues from amphibian AMPs were identi ed as G, L, A, and K. e peptide, GLK-19 (Table 1) , was previously de novo designed using only G, L, and K residues. GLK-19 was found to be active against Gram-negative E. coli but not Gram-positive Staphylococcus aureus [17] . Because only AMPs with antiviral activity are known to have an R/K ratio greater than one in our database, GLR-19 was designed by converting all lysines to arginines. While GLK-19 showed no HIV-1 inhibitory activity at a peptide concentration of 100 g/ml, GLR-19 was found to be active against both HIV-1 [19] and HSV-2 (Table 1 ). In this study, we have designed a series of peptides with loop structures based on the linear peptide GLR-19 ( Figure 1 ). We demonstrated that the anti-HIV activity of the peptide was also dependent on the loop size. While GLRC-2 with a medium 13-residue loop was the most potent against HIV-1, GLRC-3 with a small 9-residue loop was the most active against E. coli. It is evident that the optimal design of an antimicrobial peptide is microbe dependent.
Because these de novo designed peptides have a relatively simple amino acid composition, we also investigated possible structureactivity correlations. In the case of E. coli, there was no clear correlation between peptide activity and any physical parameters listed in Table 2 , including net charge, the number of Lys or Arg, percentage of hydrophobic residues, Boman index [18] (or protein binding potential [3] , and HPLC retention time (hydrophobicity). For the GLRC peptides, however, we noticed that GLRC-7, with a minimal number of positively charged residues, was the least active against Gram-negative E. coli, whereas GLRC-6, with the highest hydrophobic content (50%), is the only peptide that was moderately active against Gram-positive B. subtilis ( Table 2 ). ese observations are in line with the current knowledge on AMPs in general [26] . It was also di cult to nd any correlation between anti-HIV activity and these peptide properties. ese observations indicate that multiple factors determine the biological activity of these AMPs. However, for the three most active GLRC peptides, their HIV inhibitory activities were found to be proportional to hydrophobicity as measured by HPLC (Tables 1  & 2 ). In particular, the higher activity of GLRC-2 corresponded with its higher hydrophobicity, although this correlation could not be extended to all the peptides in Table 1 . Craik and colleagues noticed that, among the HIV inhibitory plant cyclotides, cycloviolacin Y5, isolated from the traditional Chinese herb Viola yedoensis, was the most hydrophobic and also the most potent [27] . ey proposed that cycloviolacin Y5 acted on viral membranes. Whether GLRC-2 acts by the same mechanism remains to be established. Interestingly, GLRC-2 also showed higher stability to the action of chymotrypsin compared to the other members of the GLRC peptide family as well as to its linear template GLR-19 ( Figure 2 ).
In summary, we have demonstrated the enhancement of anti-HIV activity of linear AMPs that tend to form amphipathic helical structures using the Lys-to-Arg mutational strategy [19] . We illustrated here that anti-HIV activity of SB1, a thanatin analog with a -hairpin fold, could also be improved by the same strategy [19] . Our current study has expanded our knowledge of the relationship between AMP structure and anti-HIV activity. In addition to peptide length, sequence order, charge, amino acid type, and structure [13, 19] , peptide sca olds or folds also play a pivotal role (Tables 1 & 2) . Evaluation of peptides with varying sca olds is important because of their di erent susceptibilities to proteases (Figure 2 ). is study led to the discovery of a novel peptide GLRC-2 that demonstrated both greater anti-HIV activity and greater stability to chymotrypsin over the GLR-19 template. ese results should be helpful for our future design of highly potent anti-HIV peptides with desired stability. In addition, our studies may also contribute to the identi cation of novel antimicrobial agents with activity against other viral and bacterial pathogens.
